AR and prostate cancer: The POI ligand is a derivative of the AR antagonistenzalutamide and similar to that of bavdegalutamide (ARV-110) developedfor prostate cancer. While TJA-107 demonstrated remarkable potency (DC50 = 155 nM) in vitro, it was totally inactive when topically administeredvia tinctures due to its poor skin retention (retention rate = 0.69± 0.16%).